Here's a question that keeps Alzheimer's researchers up at night: by the time someone shows memory problems, is it already too late? The plaques and tangles that define Alzheimer's disease don't just appear overnight. They've been building for years, maybe decades, while the person still seems perfectly fine. If we want to prevent Alzheimer's rather than just watch it happen, we need to understand those hidden years.
Enter PREVENT-AD, a Canadian study that's been doing something both simple and audacious for over twelve years: following healthy people who happen to have a parent with Alzheimer's. A report in Alzheimer's & Dementia lays out what this remarkable project has taught us about the disease that starts before the symptoms do.
The Radical Idea of Studying Healthy People
Most Alzheimer's research focuses on people who are already showing cognitive decline. Makes sense, right? Study the disease where the disease is. But this approach has a fundamental limitation: by the time symptoms appear, the brain has already sustained significant damage. You're studying the aftermath, not the process.
PREVENT-AD flipped the script. They enrolled cognitively normal older adults whose parents had sporadic Alzheimer's disease. Not the rare genetic kind that runs in families with devastating certainty, but the common kind that seems to strike somewhat randomly, though we know family history bumps up the risk.
These participants aren't sick. They're not showing symptoms. They're just statistically more likely than average to develop Alzheimer's at some point. And by watching them year after year, researchers can catch the earliest detectable changes before anyone would know something was wrong.
What Gets Measured Gets Understood
If you're going to follow healthy people for a decade waiting to see what changes, you'd better measure everything. PREVENT-AD took this seriously.
Participants undergo extensive assessment: multimodal MRI to look at brain structure and function, PET imaging to detect amyloid plaques and tau tangles, comprehensive cognitive testing, blood biomarkers, genetic analysis. The works. And they do it repeatedly, with annual follow-ups spanning over twelve years (median follow-up of eight years so far).
This longitudinal depth is rare. Most studies give you a snapshot. Maybe two snapshots if you're lucky. PREVENT-AD gives you a movie. You can watch the same person's brain over time and see what changes and when.
Why does this matter? Because Alzheimer's isn't a light switch. It doesn't go from healthy to diseased in a moment. It's a slow progression, and understanding the sequence of changes tells you where in that progression you might be able to intervene.
Finding the Smoke Before the Fire
The cohort has already enabled discoveries that wouldn't have been possible with traditional study designs. Researchers have identified early biomarker changes that precede any cognitive symptoms. They've helped validate blood-based Alzheimer's markers, which could eventually allow screening without expensive brain scans.
Perhaps most importantly, the deep phenotyping allows researchers to test new hypotheses as they emerge. When someone proposes a new theory about what causes Alzheimer's progression, PREVENT-AD has the data to check whether it holds up in real people followed over real time.
The study has also identified factors that seem to accelerate or slow progression. Not everything in the preclinical phase moves at the same pace for everyone. Some people accumulate pathology faster. Some seem to resist it. Understanding why could point toward protective factors worth enhancing or risk factors worth targeting.
The Prevention Puzzle
Here's the frustrating truth about Alzheimer's treatment: we don't have a cure, and the treatments we do have work modestly at best. Most clinical trials have failed. Some researchers think this is because we've been intervening too late. By the time someone qualifies for a trial based on symptoms, their brain has already lost too much ground.
Prevention is a different game. If you could identify people at high risk before damage accumulates, you could potentially intervene earlier. Maybe much earlier. But to design prevention trials, you need to understand the preclinical trajectory. What changes first? What changes fast? What predicts who will go on to develop symptoms and who won't?
PREVENT-AD provides this information. The characterized population and the detailed understanding of what happens before symptoms emerge make the cohort valuable for international prevention trials that are trying to stop Alzheimer's before it starts.
Playing the Long Game
Twelve years is a long time to run a study. Participants age. Some develop symptoms. Some don't. The team has to maintain consistency in methods while also adapting to new technologies and emerging questions. It's a logistical challenge as much as a scientific one.
But the payoff is data you simply cannot get any other way. Cross-sectional studies compare different people at different stages. Longitudinal studies follow the same people through changes. The difference is like comparing a photo album to a home video. Both tell you something, but one gives you continuity.
The PREVENT-AD approach has been influential enough that similar cohorts are now being established elsewhere. The realization that we need to understand the pre-symptomatic phase to ever achieve prevention has spread, and PREVENT-AD helped make that case.
What This Means for the Future
If you have a parent with Alzheimer's, studies like PREVENT-AD are working on questions that directly affect you. What's happening in brains at elevated risk? Can we detect it early? Can we do anything about it?
The answers aren't complete yet. But every year of follow-up adds more data, and patterns are emerging that weren't visible a decade ago. The goal isn't just academic understanding. It's building the foundation for interventions that could one day prevent people from ever experiencing the disease that took their parents.
Prevention requires foresight, patience, and a willingness to study people before they're sick. PREVENT-AD embodies all three. The next decade should tell us whether that investment pays off.
Reference: Bhattacharyya S, et al. (2025). The PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond. Alzheimer's & Dementia. doi: 10.1002/alz.70653 | PMID: 41020412
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.